BIXT at a glance
The past year
Chart−65.9% $0.02, close Nov 13
- From the highest close
- −74.4%
- Vs the 200-day average
- −24.6%
Short interest
History3,141 shares
- Since the last report
- +100.0%
- Days to cover
- 1.0 day
- Settled
- Sep 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 11 – Nov 17
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
BIXT price history
Loading recent earnings…
Investment thesis
What must happen next
ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital.WeakeningMateriality: High
MD&A states Bioxytran does not currently have sufficient capital resources and needs to raise approximately $3.7 million to fund about 15 months of development. If this holds, shareholders own a live pivotal-stage antiviral option; if it breaks, the lead program remains stranded science.
Watch: Bioxytran fails to complete a public/private financing or strategic relationship before the planned Q3 2026 Phase 3 start window.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A states Bioxytran does not currently have sufficient capital resources and needs to raise approximately $3.7 million to fund about.
Open source ↗ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal.HoldingMateriality: High
Item 1 describes a randomized, double-blind, placebo-controlled study in mild-to-moderate COVID-19 where PL-M patients showed higher Ct values by Day 3 and all treated subjects were above the cut-off by Day 7. Clinical differentiation is what turns a trial asset into partner interest, pricing power, and eventual commercialization value.
Watch: A Phase 3 design or result fails to separate ProLectin-M from placebo on symptom improvement or viral-clearance timing that regulators view as clinically meaningful.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 describes a randomized, double-blind, placebo-controlled study in mild-to-moderate COVID-19 where PL-M patients showed higher Ct values by Day.
Open source ↗Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors.WeakeningMateriality: Medium
FY2025 stockholders' equity was -$2,591,342, worse than -$1,791,949 at FY2024 year-end. Even good clinical data may not help current holders if survival financing is too dilutive or creditor-controlled.
Watch: New convertible debt includes reset, variable-conversion, or deep-discount terms.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 stockholders' equity was -$2,591,342, worse than -$1,791,949 at FY2024 year-end.
Open source ↗Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution.StrengtheningMateriality: Medium
FY2025 annual GAAP operating income was -$1,842,509, improved from -$2,223,068 in FY2024. Disciplined spending extends runway and increases the chance that each new share issued funds value-creating trial work rather than corporate drag.
Watch: Management resumes material stock-promotion spending before trial funding is secured.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating income was -$1,842,509, improved from -$2,223,068 in FY2024.
Open source ↗BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine.HoldingMateriality: Medium
MD&A says BXT-25 was successfully tested in animals, with initial results showing non-toxicity and full recovery in Swiss Albino mice. If BXT-25 advances, Bioxytran has a second platform-like asset beyond COVID; if it stalls, valuation rests almost entirely on ProLectin-M.
Watch: The planned rabbit and rat repeated-dose toxicity studies show toxicity or fail to support further development.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
MD&A says BXT-25 was successfully tested in animals, with initial results showing non-toxicity and full recovery in Swiss Albino mice.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital. If this holds, shareholders own a live pivotal-stage antiviral option; if it breaks, the lead program remains stranded science.
ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal. Clinical differentiation is what turns a trial asset into partner interest, pricing power, and eventual commercialization value.
Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors. Even good clinical data may not help current holders if survival financing is too dilutive or creditor-controlled.
Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution. Disciplined spending extends runway and increases the chance that each new share issued funds value-creating trial work rather than corporate drag.
BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine. If BXT-25 advances, Bioxytran has a second platform-like asset beyond COVID; if it stalls, valuation rests almost entirely on ProLectin-M.
All standing thesis claims
Original report summary
Bioxytran is a distressed clinical-stage option on galectin-antagonist antiviral data and oxygen-carrier science, with financing—not current operations—the gating variable.
Bull case and bear case
Bull case and bear case for Bioxytran
Where the evidence on Bioxytran disagrees: Mixed on the latest evidence (Nov 10, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.
Bull case: what the evidence supports
ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal.
Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution.
BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine.
Bear case: what the evidence questions
ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital.
Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors.
Thesis-Break Engine
What has broken in Bioxytran’s thesis
Each break OptimistFi flagged on Bioxytran, dated — with what has historically followed the same kind of break across the market, not a forecast for Bioxytran.
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
Bioxytran filed an SEC 8-K on 2026-11-05: Other material event. It is a dated development that tests the current thesis.
- MixedOther material event.
Bioxytran filed an SEC 8-K on 2026-08-11: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Bioxytran fails to complete a public/private financing or strategic relationship before the planned Q3 2026 Phase 3 start window.
- A Phase 3 design or result fails to separate ProLectin-M from placebo on symptom improvement or viral-clearance timing that regulators view as clinically meaningful.
- New convertible debt includes reset, variable-conversion, or deep-discount terms.
- Management resumes material stock-promotion spending before trial funding is secured.
- The planned rabbit and rat repeated-dose toxicity studies show toxicity or fail to support further development.
BIXT news
Loading headlines…
Financial statements
BIXT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
BIXT: quick answers
- What is BIXT's short interest?
- As of September 30, 2026, 3,141 BIXT shares were sold short, up 100.0% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. BIXT short interest history

